Xeris Biopharma (NASDAQ:XERS – Get Free Report) and Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.
Institutional & Insider Ownership
42.7% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 4.3% of Xeris Biopharma shares are owned by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Xeris Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xeris Biopharma | 1 | 2 | 4 | 0 | 2.43 |
| Cumberland Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Xeris Biopharma currently has a consensus target price of $10.80, indicating a potential upside of 24.28%. Given Xeris Biopharma’s stronger consensus rating and higher probable upside, research analysts plainly believe Xeris Biopharma is more favorable than Cumberland Pharmaceuticals.
Profitability
This table compares Xeris Biopharma and Cumberland Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xeris Biopharma | 3.81% | 735.00% | 3.24% |
| Cumberland Pharmaceuticals | -17.60% | -12.01% | -4.24% |
Valuation & Earnings
This table compares Xeris Biopharma and Cumberland Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xeris Biopharma | $291.85 million | 5.14 | $550,000.00 | $0.06 | 144.83 |
| Cumberland Pharmaceuticals | $44.52 million | 2.58 | -$2.84 million | ($0.49) | -15.63 |
Xeris Biopharma has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Xeris Biopharma beats Cumberland Pharmaceuticals on 13 of the 14 factors compared between the two stocks.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
